While treatments for AD are scarce, preclinical/prodromal biomarkers (e.g., amyloid β, pathological tau protein, brain atrophy) hold promise for the earlier disease detection and the development of novel interventions designed to prevent or delay AD (Dubois et al., 2014, 2021; Jack et al., 2018; Srivastava et al., 2021; Mahaman et al., 2022; Teunissen et al., 2022). This evidence concerns the gene MAPT and Alzheimer disease.